Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Integrated hypoxia and metabolic gene signature to predict clinical outcomes and therapeutic vulnerabilities in lung adenocarcinoma.

Journal of thoracic disease·2026
Same author

Extracellular vesicles derived from cancer-associated fibroblasts facilitate NSCLC progression and metastasis via miR-664b-5p-mediated activation of the CXCL12/CXCR4 chemokine pathway.

Biochimica et biophysica acta. Molecular basis of disease·2026
Same author

A pan-cancer single-cell atlas uncovers the role of sex hormones and chromosomes in sex-divergent reprogramming of the tumor microenvironment.

Cell communication and signaling : CCS·2026
Same author

Serplulimab Plus Chemotherapy, with or without HLX04, versus Chemotherapy as First-Line Treatment for Nonsquamous NSCLC: Final Survival Analysis of the Phase III ASTRUM-002 Study.

Cancer communications (London, England)·2026
Same author

SIRT5-mediated FDX1 desuccinylation confers cuproptosis resistance in lung adenocarcinoma.

Cell reports·2026
Same author

Risk factors for non-curative resection after endoscopic submucosal dissection for early esophageal lesions and analysis of secondary treatment efficacy.

Surgical endoscopy·2026

Related Experiment Video

Updated: Jul 10, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Ensartinib in Resected ALK-Positive Non-Small-Cell Lung Cancer.

Dongsheng Yue1, Meijuan Huang2, Pingping Song3

  • 1Department of Lung Cancer, Tianjin Medical University Institute and Hospital, Tianjin, China.

The New England Journal of Medicine
|July 8, 2026
PubMed
Summary

Ensartinib significantly improved disease-free survival in patients with resectable ALK-positive non-small-cell lung cancer. This second-generation ALK inhibitor demonstrated superior efficacy compared to placebo in a phase 3 trial.

More Related Videos

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
06:43

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib

Published on: April 3, 2026

Related Experiment Videos

Last Updated: Jul 10, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
06:43

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib

Published on: April 3, 2026

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Trials

Background:

  • Anaplastic lymphoma kinase (ALK) inhibitors are key treatments for ALK-positive non-small-cell lung cancer (NSCLC).
  • The efficacy and safety of ensartinib, a second-generation ALK inhibitor, in resectable ALK-positive NSCLC remain under investigation.

Purpose of the Study:

  • To evaluate the efficacy and safety of ensartinib compared to placebo in patients with completely resected, ALK-positive stage IB to IIIB NSCLC.
  • To determine the impact of ensartinib on disease-free survival in this patient population.

Main Methods:

  • A phase 3, double-blind, randomized trial was conducted with 274 patients.
  • Patients received either ensartinib (225 mg daily) or placebo for 24 months post-adjuvant chemotherapy.
  • Disease-free survival was assessed as the primary and key secondary end point.

Main Results:

  • At 24 months, disease-free survival was 86.4% with ensartinib versus 53.5% with placebo in stage II-IIIB NSCLC (hazard ratio: 0.20; P<0.001).
  • In the overall population, disease-free survival was 87.3% with ensartinib versus 57.2% with placebo (hazard ratio: 0.20; P<0.001).
  • Grade 3 or higher adverse events occurred in 35.8% receiving ensartinib versus 18.2% receiving placebo.

Conclusions:

  • Ensartinib significantly increases disease-free survival in patients with resectable ALK-positive NSCLC compared to placebo.
  • Ensartinib is a promising therapeutic option for this patient group, warranting further investigation into overall survival outcomes.